inhibitor (Deutetrabenazine) is proved to be effective in the cure of involuntary movements in patients with tardive dyskinesia, and the SLC18A2 blocker (Tetrabenazine) is the only US Food and Drug Administration-approved drug for Huntington’s disease (Hu et al., 2020). The gene discussed is SLC18A2; the disease is juvenile Huntington disease.